Intravenous Immunoglobulin Market Outlook

Recent advancements underscore the evolving nature of the IVIG space. For example, Evolve Biologics has completed a Phase III clinical study for its IVIG product, with regulatory filing anticipated in 2027. This marks a notable development in plasma-derived therapy, leveraging the company’s proprietary PlasmaCap EBA purification platform.

Broader pipeline analysis indicates continued exploration of innovative therapeutic strategies aimed at improving disease outcomes. Industry leaders—including CSL Behring, Grifols, Octapharma, Kedrion, Takeda Pharmaceutical, Baxter International, ADMA Biologics, LFB Biotechnologies, Biotest AG, Shanghai RAAS Blood Products, China Biologics Products, BDI Pharma, and Intas Pharmaceuticals—are actively investing in next-generation IVIG formulations designed to enhance efficacy, safety, and patient convenience.

1. Takeda Pharmaceutical Company Limited

Company & Country:
Takeda Pharmaceutical Company Limited — Japan (Headquarters in Tokyo/Osaka)

Product / Drug Candidate:

• Immune Globulin (liquid IVIG), including Kenketsu GLOVENIN-I 10% (IVIG)
• HYQVIA® (facilitated subcutaneous immunoglobulin / fSCIG) (IVIG + recombinant hyaluronidase)

Clinical Trial Phases & Registry IDs:

• Phase 3:
• • Liquid IVIG (improved Kenketsu GLOVENIN-I 10% IV formulation) — regulatory approval achieved in Japan (new formulation) with supportive Phase 3 data (JMA reviews).
• Phase 3 (SCIG / fSCIG):
• • HYQVIA® pivotal Phase 3 trials included NCT05150340 and NCT05513586 for agammaglobulinemia/hypogammaglobulinemia in Japan (registrations listed in press releases).
• Long-term Extension / Maintenance (Phase 3 / ongoing):
• • ADVANCE-CIDP 3 (Phase 3 extension in chronic inflammatory demyelinating polyneuropathy) leveraging HYQVIA (NCT02955355).

Mechanism of Action (MOA):

• IVIG / Immune Globulin: Polyclonal human IgG pooled from plasma donors that provides immune replacement (in immunodeficiency) and immunomodulatory effects via Fc receptor blockade, anti-idiotype interactions, and cytokine modulation.
• HYQVIA: Combines IVIG with recombinant human hyaluronidase (rHuPH20) to enhance dispersion and absorption subcutaneously — functionally similar immunoglobulin replacement with improved delivery characteristics.

Latest News / Updates:

• Approval of Kenketsu GLOVENIN-I 10% IVIG in Japan (Feb 2026), reflecting regulatory advancement of improved IVIG formulation.
• Multiple Phase 3 outcomes supporting safety and expanded clinical utility of HYQVIA in immunodeficiency and neuroinflammatory disorders.